{"protocolSection":{"identificationModule":{"nctId":"NCT05616013","orgStudyIdInfo":{"id":"18828"},"secondaryIdInfos":[{"id":"J4Z-MC-GIDA","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"VER201-PH2-031","type":"OTHER","domain":"Versanis"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women"},"statusModule":{"statusVerifiedDate":"2026-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-11-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-05-16","type":"ACTUAL"},"completionDateStruct":{"date":"2025-06-14","type":"ACTUAL"},"studyFirstSubmitDate":"2022-10-16","studyFirstSubmitQcDate":"2022-11-09","studyFirstPostDateStruct":{"date":"2022-11-14","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-05-16","resultsFirstSubmitQcDate":"2025-06-27","resultsFirstPostDateStruct":{"date":"2025-07-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-06-11","lastUpdatePostDateStruct":{"date":"2026-07-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"},"collaborators":[{"name":"Versanis Bio, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women","detailedDescription":"This study investigates if bimagrumab in addition to semaglutide is able to preserve/increase muscle mass in the presence of weight and/or fat mass loss."},"conditionsModule":{"conditions":["Obesity","Obese","Overweight or Obesity"],"keywords":["bimagrumab","semaglutide"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"FACTORIAL","interventionModelDescription":"The study is designed to have three periods. The 48-week core treatment period has 9 treatment arms, with combinations of 3 semaglutide doses (none, 1.0 mg and 2.4 mg) and 3 bimagrumab doses (0, 10 and 30 mg/kg). The core treatment period is then followed by an open-label 24-week treatment extension period during which participants originally assigned to either placebo or bimagrumab 10 mg/kg will switch to bimagrumab 30 mg/kg. All other treatment assignments will remain the same. The extension period is then followed by a 32-week post-treatment period, during which all study treatments will be withdrawn from all arms.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","maskingDescription":"In regard to bimagrumab and placebo-bimagrumab, the participants, Investigator and Sponsor will be blinded.\n\nDue to semaglutide being pre-filled, packaged and labeled by manufacturer, it is not possible to blind semaglutide.","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":507,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo/30 mg/kg Bimagrumab","type":"PLACEBO_COMPARATOR","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64.","interventionNames":["Other: Placebo"]},{"label":"10/30 mg/kg Bimagrumab","type":"EXPERIMENTAL","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64.","interventionNames":["Biological: Bimagrumab"]},{"label":"30 mg/kg Bimagrumab","type":"EXPERIMENTAL","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64.","interventionNames":["Biological: Bimagrumab"]},{"label":"Placebo + 1.0 mg Semaglutide","type":"EXPERIMENTAL","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg","interventionNames":["Drug: Semaglutide","Other: Placebo"]},{"label":"Placebo + 2.4 mg Semaglutide","type":"EXPERIMENTAL","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg","interventionNames":["Drug: Semaglutide","Other: Placebo"]},{"label":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","type":"EXPERIMENTAL","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg","interventionNames":["Biological: Bimagrumab","Drug: Semaglutide"]},{"label":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","type":"EXPERIMENTAL","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg","interventionNames":["Biological: Bimagrumab","Drug: Semaglutide"]},{"label":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","type":"EXPERIMENTAL","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg","interventionNames":["Biological: Bimagrumab","Drug: Semaglutide"]},{"label":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","type":"EXPERIMENTAL","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg","interventionNames":["Biological: Bimagrumab","Drug: Semaglutide"]}],"interventions":[{"type":"BIOLOGICAL","name":"Bimagrumab","description":"Human monoclonal antibody to the activin receptor type II","armGroupLabels":["10 mg/kg Bimagrumab + 1.0 mg Semaglutide","10 mg/kg Bimagrumab + 2.4 mg Semaglutide","10/30 mg/kg Bimagrumab","30 mg/kg Bimagrumab","30 mg/kg Bimagrumab + 1.0 mg Semaglutide","30 mg/kg Bimagrumab + 2.4 mg Semaglutide"]},{"type":"DRUG","name":"Semaglutide","description":"Glucagon-like peptide-1 (GLP-1) receptor agonist","armGroupLabels":["10 mg/kg Bimagrumab + 1.0 mg Semaglutide","10 mg/kg Bimagrumab + 2.4 mg Semaglutide","30 mg/kg Bimagrumab + 1.0 mg Semaglutide","30 mg/kg Bimagrumab + 2.4 mg Semaglutide","Placebo + 1.0 mg Semaglutide","Placebo + 2.4 mg Semaglutide"],"otherNames":["Wegovy","Ozempic"]},{"type":"OTHER","name":"Placebo","description":"Placebo","armGroupLabels":["Placebo + 1.0 mg Semaglutide","Placebo + 2.4 mg Semaglutide","Placebo/30 mg/kg Bimagrumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Body Weight at Week 48","description":"Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 48"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Waist Circumference at Week 48","description":"Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 centimeter (cm). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 48"},{"measure":"Change From Baseline in Waist Circumference at Week 72","description":"Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 72"},{"measure":"Change From Baseline in Total Body Fat Mass in Kilograms (kg) at Week 48","description":"Change from baseline in total body fat mass in kg was assessed by Dual energy X-ray absorptiometry (DXA). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 48"},{"measure":"Change From Baseline in Total Body Fat Mass in kg at Week 72","description":"Change from baseline in total body fat mass in kg was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 72"},{"measure":"Percent Change From Baseline for Fat Mass by DXA at Week 48","description":"Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 48"},{"measure":"Percent Change From Baseline for Fat Mass by DXA at Week 72","description":"Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 72"},{"measure":"Change From Baseline in Visceral Adipose Tissue (VAT), Subcutaneous Adipose Tissue (SAT) and Trunk Fat Mass by DXA at Week 48","description":"Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 48"},{"measure":"Change From Baseline in VAT, SAT and Trunk Fat Mass by DXA at Week 72","description":"Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 72"},{"measure":"Percentage of Participants With Reduction in Waist Circumference Greater Than or Equal to (≥) 5 cm at Week 48","description":"Waist circumference was measured in a standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Only participants with non-missing baseline value were included in analysis.","timeFrame":"Week 48"},{"measure":"Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48","description":"Body weight was measured in kgs to the nearest 0.1 kg. Only participants with non-missing baseline value were included in analysis.","timeFrame":"Week 48"},{"measure":"Percentage of Participants With Reduction in Fat Mass ≥ 5% ≥ 10% ≥ 15% by DXA at Week 48","description":"Only participants with non-missing baseline value were included in analysis.","timeFrame":"Week 48"},{"measure":"Percentage of Participants Achieving Fat Mass ≥ 10% Reduction With <5% Decrease in Lean Mass by DXA at Week 48","description":"Only participants with non-missing baseline value were included in analysis.","timeFrame":"Week 48"},{"measure":"Percentage of Participants Achieving >5 kg Weight Loss and Fat Loss Index (FLI) of >70%, >80%, and >90% by DXA at Week 48","description":"Fat Lost Index = % change in fat mass/% change in lean mass + % change in fat mass. Only participants with non-missing baseline value were included in analysis.","timeFrame":"Week 48"},{"measure":"Change From Baseline in Body Fat Mass by Bioelectrical Impedance Analysis (BIA) at Week 48","description":"Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","timeFrame":"Baseline, Week 48"},{"measure":"Change From Baseline in Body Fat Mass by BIA at Week 72","description":"Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","timeFrame":"Baseline, Week 72"},{"measure":"Percent Change From Baseline in Body Fat by BIA at Week 48","description":"Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","timeFrame":"Baseline, Week 48"},{"measure":"Percent Change From Baseline in Body Fat by BIA at Week 72","description":"Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","timeFrame":"Baseline, Week 72"},{"measure":"Change From Baseline in Lean Mass by DXA at Week 48","description":"Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 48"},{"measure":"Change From Baseline in Lean Mass by DXA at Week 72","description":"Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 72"},{"measure":"Percent Change From Baseline in Lean Body Mass by DXA at Week 48","description":"Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 48"},{"measure":"Percent Change From Baseline in Lean Body Mass by DXA at Week 72","description":"Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 72"},{"measure":"Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 48","description":"Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 48"},{"measure":"Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 72","description":"Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, Week 72"},{"measure":"Change From Baseline in Lean Mass (kg) by BIA at Week 48","description":"Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","timeFrame":"Baseline, Week 48"},{"measure":"Change From Baseline in Lean Mass (kg) by BIA at Week 72","description":"Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","timeFrame":"Baseline, Week 72"},{"measure":"Percent Change From Baseline in Lean Body Mass by BIA at Week 48","description":"Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","timeFrame":"Baseline, Week 48"},{"measure":"Percent Change From Baseline in Lean Body Mass by BIA at Week 72","description":"Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","timeFrame":"Baseline, Week 72"},{"measure":"Percentage of Participants With Body Mass Index (BMI) Categories at Baseline and Week 48","description":"BMI categories:\n\ni. Healthy weight: 18.5 kilograms (kg)/meter (m)² to 24.9 kg/m² ii. Overweight: 25 kg/m² to 29.9 kg/m² iii. Obesity class 1: 30 kg/m² to 34.9 kg/m² iv. Obesity class II: 35 kg/m² to 39.9 kg/m² v. Obesity class III: ≥ 40 kg/m2","timeFrame":"Baseline, Week 48"},{"measure":"Percentage of Participants With Baseline Waist-to-Height Ratio (WtHR) Category of <0.5 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48","description":"WHtR ratio categories: \\<0.5; 0.5-0.59; ≥0.6","timeFrame":"Baseline up to 48 weeks"},{"measure":"Percentage of Participants With Baseline WtHR Category of 0.5-0.59 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48","description":"WHtR ratio categories: \\<0.5; 0.5-0.59; ≥0.6","timeFrame":"Baseline up to 48 weeks"},{"measure":"Percentage of Participants With Baseline WtHR Category ≥0.6 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48","description":"WHtR ratio categories: \\<0.5; 0.5-0.59; ≥0.6","timeFrame":"Baseline up to 48 weeks"},{"measure":"Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 48","description":"HbA1c is the glycosylated fraction of hemoglobin A. It is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","timeFrame":"Baseline, 48 weeks"},{"measure":"Change From Baseline in Quality of Life Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 24","description":"The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health \"now\" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores.","timeFrame":"Baseline, Week 24"},{"measure":"Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score Week 24","description":"The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into (mental component score \\[MCS\\] and physical component score \\[PCS\\] to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.","timeFrame":"Baseline, Week 24"},{"measure":"Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 48","description":"The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health \"now\" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores","timeFrame":"Baseline, Week 48"},{"measure":"Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 48","description":"The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.","timeFrame":"Baseline, Week 48"},{"measure":"Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 72","description":"The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health \"now\" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores","timeFrame":"Baseline, Week 72"},{"measure":"Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 72","description":"The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.","timeFrame":"Baseline, Week 72"},{"measure":"Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score and Total Score at Week 24","description":"The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'","timeFrame":"Baseline, Week 24"},{"measure":"Change From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 48","description":"The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'","timeFrame":"Baseline, Week 48"},{"measure":"Change From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 72","description":"The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'","timeFrame":"Baseline, Week 72"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* A written informed consent must be obtained before any study-related assessments are performed.\n* Men and women between 18 and 80 years, inclusive; women of child-bearing potential (defined as those who are not post-menopausal or post-surgical sterilization) must meet both of the following criteria:\n\n  * Two negative pregnancy tests (at screening and at randomization, prior to dosing)\n  * Use of intrauterine device, from at least 3 months before the baseline visit through at least 4 months after the last dose of bimagrumab/placebo i.v., and an additional contraceptive (barrier) method from screening through at least 4 months after the last dose of bimagrumab/placebo i.v.\n* Body mass index (BMI) ≥ 30 or BMI ≥ 27 with one or more obesity-associated comorbidities (e.g., hypertension, insulin resistance, sleep apnea, or dyslipidemia)\n* Stable body weight (± 5 kg) within 90 days of screening, and body weight \\<150 kg\n* Have a history of at least one self-reported unsuccessful behavioral effort to lose body weight\n* Able to communicate well with the Investigator, comply with the study requirements and adhere to the diet and activity programs for the study duration\n\nKey Exclusion Criteria:\n\n* History of, or known hypersensitivity to, monoclonal antibody drugs or a contraindication to semaglutide (Ozempic® or Wegovy®)\n* Use of other investigational drugs at the time of enrollment or within 30 days or 5 half-lives of enrollment, whichever is longer, or longer if required by local regulations\n* Treatment with any medication for the indication of obesity within the past 30 days before screening\n* Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c ≥ 6.5% Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed exclusively with non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion.\n* Any chronic infections likely to interfere with study conduct or interpretation such as hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV). History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active COVID-19 infection.\n* Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing, or longer if required by local regulation, or plasma donation (\\> 250 mL) within 14 days prior to the first dose\n* Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the participant's safety or compliance with the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pinnacle Research Group, LLC","city":"Anniston","state":"Alabama","zip":"36207","country":"United States","geoPoint":{"lat":33.65983,"lon":-85.83163}},{"facility":"Cullman Clinical Trials","city":"Cullman","state":"Alabama","zip":"35055","country":"United States","geoPoint":{"lat":34.17482,"lon":-86.84361}},{"facility":"Indago Research & Health Center, Inc","city":"Hialeah","state":"Florida","zip":"33012","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"Clinical Neuroscience Solutions Inc","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Altus Research","city":"Lake Worth","state":"Florida","zip":"33461","country":"United States","geoPoint":{"lat":26.61708,"lon":-80.07231}},{"facility":"Pennington Biomedical Research Center","city":"Baton Rouge","state":"Louisiana","zip":"70808","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"Weill Cornell Medical College","city":"New York","state":"New York","zip":"10021","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Monroe Biomedical Research","city":"Monroe","state":"North Carolina","zip":"28112","country":"United States","geoPoint":{"lat":34.98543,"lon":-80.54951}},{"facility":"SPICA Clinical","city":"Columbia","state":"South Carolina","zip":"29322","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"Mt. Olympus Medical Research","city":"Sugar Land","state":"Texas","zip":"77479","country":"United States","geoPoint":{"lat":29.61968,"lon":-95.63495}},{"facility":"Northern Beaches Clinical Research","city":"Brookvale","state":"New South Wales","zip":"2100","country":"Australia","geoPoint":{"lat":-33.76108,"lon":151.27446}},{"facility":"Royal North Shore Hospital","city":"Saint Leonards","state":"New South Wales","zip":"2065","country":"Australia"},{"facility":"University of The Sunshine Coast Morayfield","city":"Morayfield","state":"Queensland","zip":"4506","country":"Australia","geoPoint":{"lat":-27.10876,"lon":152.94907}},{"facility":"University of the Sunshine Coast Clinical Trial Centre","city":"Sippy Downs","state":"Queensland","zip":"04556","country":"Australia","geoPoint":{"lat":-26.71793,"lon":153.05475}},{"facility":"University of The Sunshine Coast South Brisbane","city":"South Brisbane","state":"Queensland","zip":"4101","country":"Australia","geoPoint":{"lat":-27.48034,"lon":153.02049}},{"facility":"Gold Coast University Hospital","city":"Southport","state":"Queensland","zip":"4215","country":"Australia","geoPoint":{"lat":-27.96724,"lon":153.39796}},{"facility":"Austin Health","city":"Heidelberg Heights","state":"Victoria","zip":"3081","country":"Australia","geoPoint":{"lat":-37.74313,"lon":145.05695}},{"facility":"Emeritus Research","city":"Camberwell","zip":"3124","country":"Australia","geoPoint":{"lat":-37.84205,"lon":145.0694}},{"facility":"Southern Clinical Trials Ltd","city":"Beckenham, Christchurch","state":"Canterbury","zip":"8013","country":"New Zealand"},{"facility":"P3 Research","city":"Newtown","state":"Wellington Region","zip":"6242","country":"New Zealand","geoPoint":{"lat":-41.31115,"lon":174.77935}},{"facility":"New Zealand Clinical Research Auckland","city":"Auckland","zip":"1010","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Optimal Clinical Trials","city":"Auckland","zip":"1010","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Middlemore Hospital","city":"Auckland","zip":"2025","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"New Zealand Clinical Research Christchurch","city":"Christchurch","zip":"8011","country":"New Zealand","geoPoint":{"lat":-43.53333,"lon":172.63333}},{"facility":"Lakeland Clinical Trials Waikato","city":"Hamilton","zip":"3200","country":"New Zealand","geoPoint":{"lat":-37.78333,"lon":175.28333}},{"facility":"Southern Clinical Trials Tasman","city":"Nelson","zip":"7011","country":"New Zealand","geoPoint":{"lat":-41.27078,"lon":173.28404}}]},"referencesModule":{"references":[{"pmid":"41772149","type":"DERIVED","citation":"Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM; BELIEVE trial investigators. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026 Mar;32(3):869-882. doi: 10.1038/s41591-026-04204-0. Epub 2026 Mar 2."},{"pmid":"40230053","type":"DERIVED","citation":"Moon S, Choi JW, Park JH, Kim DS, Ahn Y, Kim Y, Kong SH, Oh CM. Association of Appendicular Skeletal Muscle Mass Index and Insulin Resistance With Mortality in Multi-Nationwide Cohorts. J Cachexia Sarcopenia Muscle. 2025 Apr;16(2):e13811. doi: 10.1002/jcsm.13811."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"http://vivli.org/"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"FG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"FG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"FG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"FG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"FG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"FG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"FG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"FG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"56"},{"groupId":"FG002","numSubjects":"57"},{"groupId":"FG003","numSubjects":"56"},{"groupId":"FG004","numSubjects":"57"},{"groupId":"FG005","numSubjects":"56"},{"groupId":"FG006","numSubjects":"56"},{"groupId":"FG007","numSubjects":"56"},{"groupId":"FG008","numSubjects":"57"}]},{"type":"Safety Analysis Population (Received at Least 1 Dose of Study Drug)","achievements":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"56"},{"groupId":"FG002","numSubjects":"57"},{"groupId":"FG003","numSubjects":"55"},{"groupId":"FG004","numSubjects":"56"},{"groupId":"FG005","numSubjects":"56"},{"groupId":"FG006","numSubjects":"55"},{"groupId":"FG007","numSubjects":"56"},{"groupId":"FG008","numSubjects":"55"}]},{"type":"COMPLETED","comment":"\"Completer\" includes participants who completed all protocol-scheduled visits until Week 104.","achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"25"},{"groupId":"FG002","numSubjects":"27"},{"groupId":"FG003","numSubjects":"33"},{"groupId":"FG004","numSubjects":"39"},{"groupId":"FG005","numSubjects":"28"},{"groupId":"FG006","numSubjects":"35"},{"groupId":"FG007","numSubjects":"37"},{"groupId":"FG008","numSubjects":"35"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"31"},{"groupId":"FG002","numSubjects":"30"},{"groupId":"FG003","numSubjects":"23"},{"groupId":"FG004","numSubjects":"18"},{"groupId":"FG005","numSubjects":"28"},{"groupId":"FG006","numSubjects":"21"},{"groupId":"FG007","numSubjects":"19"},{"groupId":"FG008","numSubjects":"22"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"6"},{"groupId":"FG008","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"9"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"6"}]},{"type":"Non-compliance with study requirements","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"4"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"8"},{"groupId":"FG007","numSubjects":"10"},{"groupId":"FG008","numSubjects":"7"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"2"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants.","groups":[{"id":"BG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"BG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"BG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"BG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"BG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"BG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"BG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"BG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"BG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"BG009","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"57"},{"groupId":"BG003","value":"56"},{"groupId":"BG004","value":"57"},{"groupId":"BG005","value":"56"},{"groupId":"BG006","value":"56"},{"groupId":"BG007","value":"56"},{"groupId":"BG008","value":"57"},{"groupId":"BG009","value":"507"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47.8","spread":"14.6"},{"groupId":"BG001","value":"44.4","spread":"10.9"},{"groupId":"BG002","value":"49.2","spread":"12.2"},{"groupId":"BG003","value":"50.3","spread":"11.2"},{"groupId":"BG004","value":"49.6","spread":"11.8"},{"groupId":"BG005","value":"44.8","spread":"12.0"},{"groupId":"BG006","value":"46.2","spread":"11.7"},{"groupId":"BG007","value":"47.7","spread":"10.4"},{"groupId":"BG008","value":"47.5","spread":"12.7"},{"groupId":"BG009","value":"47.5","spread":"12.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"32"},{"groupId":"BG004","value":"33"},{"groupId":"BG005","value":"32"},{"groupId":"BG006","value":"32"},{"groupId":"BG007","value":"32"},{"groupId":"BG008","value":"33"},{"groupId":"BG009","value":"291"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"24"},{"groupId":"BG007","value":"24"},{"groupId":"BG008","value":"24"},{"groupId":"BG009","value":"216"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"7"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"8"},{"groupId":"BG009","value":"53"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"53"},{"groupId":"BG003","value":"52"},{"groupId":"BG004","value":"54"},{"groupId":"BG005","value":"50"},{"groupId":"BG006","value":"49"},{"groupId":"BG007","value":"47"},{"groupId":"BG008","value":"48"},{"groupId":"BG009","value":"445"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"9"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"3"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"15"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"6"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"46"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"24"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"36"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"45"},{"groupId":"BG003","value":"40"},{"groupId":"BG004","value":"46"},{"groupId":"BG005","value":"41"},{"groupId":"BG006","value":"39"},{"groupId":"BG007","value":"43"},{"groupId":"BG008","value":"45"},{"groupId":"BG009","value":"381"}]}]},{"title":"Multiple","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"2"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"19"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"7"},{"groupId":"BG007","value":"14"},{"groupId":"BG008","value":"14"},{"groupId":"BG009","value":"105"}]}]},{"title":"New Zealand","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"23"},{"groupId":"BG005","value":"25"},{"groupId":"BG006","value":"30"},{"groupId":"BG007","value":"24"},{"groupId":"BG008","value":"23"},{"groupId":"BG009","value":"222"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"19"},{"groupId":"BG007","value":"18"},{"groupId":"BG008","value":"20"},{"groupId":"BG009","value":"180"}]}]}]},{"title":"Body Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilogram (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"109.55","spread":"19.33"},{"groupId":"BG001","value":"105.12","spread":"19.50"},{"groupId":"BG002","value":"109.05","spread":"17.56"},{"groupId":"BG003","value":"105.81","spread":"20.02"},{"groupId":"BG004","value":"104.50","spread":"14.82"},{"groupId":"BG005","value":"108.36","spread":"18.92"},{"groupId":"BG006","value":"108.78","spread":"18.41"},{"groupId":"BG007","value":"108.19","spread":"14.34"},{"groupId":"BG008","value":"108.12","spread":"18.48"},{"groupId":"BG009","value":"107.50","spread":"17.97"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Body Weight at Week 48","description":"Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kilogram (kg)","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.31","spread":"1.39"},{"groupId":"OG001","value":"-5.99","spread":"1.42"},{"groupId":"OG002","value":"-9.25","spread":"1.33"},{"groupId":"OG003","value":"-9.76","spread":"1.25"},{"groupId":"OG004","value":"-14.24","spread":"1.17"},{"groupId":"OG005","value":"-12.73","spread":"1.29"},{"groupId":"OG006","value":"-14.31","spread":"1.34"},{"groupId":"OG007","value":"-13.86","spread":"1.29"},{"groupId":"OG008","value":"-17.79","spread":"1.29"}]}]}],"analyses":[{"groupIds":["OG000","OG008"],"groupDescription":"Bima 30mg/kg + Sema 2.4mg vs Placebo","nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"LS Mean Change difference","paramValue":"-14.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-18.0","ciUpperLimit":"-11.0"},{"groupIds":["OG000","OG007"],"groupDescription":"Bima 30mg/kg + Sema 1.0mg vs Placebo","nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"LS Mean Change difference","paramValue":"-10.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.0","ciUpperLimit":"-7.09"},{"groupIds":["OG000","OG006"],"groupDescription":"Bima 10mg/kg + Sema 2.4mg vs Placebo","nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"LS Mean Change difference","paramValue":"-11.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.4","ciUpperLimit":"-7.55"},{"groupIds":["OG000","OG005"],"groupDescription":"Bima 10mg/kg + Sema 1.0mg vs Placebo","nonInferiorityType":"SUPERIORITY","pValue":"<.001","statisticalMethod":"ANCOVA","paramType":"LS Mean Change difference","paramValue":"-9.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.9","ciUpperLimit":"-5.93"},{"groupIds":["OG000","OG004"],"groupDescription":"Sema 2.4mg vs Placebo","nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"LS Mean Change difference","paramValue":"-10.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.4","ciUpperLimit":"-7.46"},{"groupIds":["OG000","OG003"],"groupDescription":"Sema 1.0mg vs Placebo","nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"LS Mean Change difference","paramValue":"-6.45","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.96","ciUpperLimit":"-2.94"},{"groupIds":["OG000","OG002"],"groupDescription":"Bima 30mg/kg vs Placebo","nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"LS Mean Change difference","paramValue":"-5.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.47","ciUpperLimit":"-2.41"},{"groupIds":["OG000","OG001"],"groupDescription":"Bima 10mg/kg vs Placebo","nonInferiorityType":"SUPERIORITY","pValue":"0.133","statisticalMethod":"ANCOVA","paramType":"LS Mean Change difference","paramValue":"-2.68","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.18","ciUpperLimit":"0.82"}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference at Week 48","description":"Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 centimeter (cm). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"centimeter (cm)","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"39"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.71","spread":"1.27"},{"groupId":"OG001","value":"-7.88","spread":"1.28"},{"groupId":"OG002","value":"-10.64","spread":"1.16"},{"groupId":"OG003","value":"-10.57","spread":"1.22"},{"groupId":"OG004","value":"-13.60","spread":"1.11"},{"groupId":"OG005","value":"-14.63","spread":"0.90"},{"groupId":"OG006","value":"-16.55","spread":"1.00"},{"groupId":"OG007","value":"-15.84","spread":"1.10"},{"groupId":"OG008","value":"-19.03","spread":"1.09"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference at Week 72","description":"Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"centimeter (cm)","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"45"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"39"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.89","spread":"1.32"},{"groupId":"OG001","value":"-9.59","spread":"1.51"},{"groupId":"OG002","value":"-13.04","spread":"1.30"},{"groupId":"OG003","value":"-10.40","spread":"1.41"},{"groupId":"OG004","value":"-14.67","spread":"1.33"},{"groupId":"OG005","value":"-15.59","spread":"1.07"},{"groupId":"OG006","value":"-18.10","spread":"1.24"},{"groupId":"OG007","value":"-18.21","spread":"1.30"},{"groupId":"OG008","value":"-21.26","spread":"1.26"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Body Fat Mass in Kilograms (kg) at Week 48","description":"Change from baseline in total body fat mass in kg was assessed by Dual energy X-ray absorptiometry (DXA). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Kilogram (kg)","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"47"},{"groupId":"OG005","value":"42"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.41","spread":"0.76"},{"groupId":"OG001","value":"-6.90","spread":"0.88"},{"groupId":"OG002","value":"-11.86","spread":"1.03"},{"groupId":"OG003","value":"-7.49","spread":"0.96"},{"groupId":"OG004","value":"-11.06","spread":"0.86"},{"groupId":"OG005","value":"-14.17","spread":"0.84"},{"groupId":"OG006","value":"-15.93","spread":"0.85"},{"groupId":"OG007","value":"-15.33","spread":"0.94"},{"groupId":"OG008","value":"-19.30","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Body Fat Mass in kg at Week 72","description":"Change from baseline in total body fat mass in kg was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Kilogram (kg)","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"32"},{"groupId":"OG006","value":"38"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.33","spread":"0.87"},{"groupId":"OG001","value":"-7.84","spread":"1.17"},{"groupId":"OG002","value":"-13.24","spread":"1.19"},{"groupId":"OG003","value":"-7.66","spread":"1.08"},{"groupId":"OG004","value":"-12.47","spread":"1.07"},{"groupId":"OG005","value":"-15.85","spread":"1.10"},{"groupId":"OG006","value":"-17.52","spread":"1.13"},{"groupId":"OG007","value":"-16.72","spread":"1.19"},{"groupId":"OG008","value":"-21.24","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline for Fat Mass by DXA at Week 48","description":"Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"47"},{"groupId":"OG005","value":"42"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.53","spread":"1.59"},{"groupId":"OG001","value":"-15.65","spread":"1.97"},{"groupId":"OG002","value":"-25.23","spread":"2.20"},{"groupId":"OG003","value":"-18.36","spread":"2.28"},{"groupId":"OG004","value":"-24.57","spread":"1.57"},{"groupId":"OG005","value":"-30.60","spread":"1.70"},{"groupId":"OG006","value":"-35.85","spread":"1.91"},{"groupId":"OG007","value":"-34.42","spread":"2.02"},{"groupId":"OG008","value":"-42.06","spread":"1.81"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline for Fat Mass by DXA at Week 72","description":"Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"32"},{"groupId":"OG006","value":"38"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.60","spread":"2.11"},{"groupId":"OG001","value":"-18.45","spread":"2.65"},{"groupId":"OG002","value":"-28.35","spread":"2.45"},{"groupId":"OG003","value":"-18.97","spread":"2.55"},{"groupId":"OG004","value":"-27.37","spread":"2.11"},{"groupId":"OG005","value":"-33.58","spread":"2.12"},{"groupId":"OG006","value":"-39.46","spread":"2.46"},{"groupId":"OG007","value":"-37.26","spread":"2.48"},{"groupId":"OG008","value":"-45.42","spread":"2.12"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Visceral Adipose Tissue (VAT), Subcutaneous Adipose Tissue (SAT) and Trunk Fat Mass by DXA at Week 48","description":"Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome. Number analysed are the participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"47"},{"groupId":"OG005","value":"42"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"43"}]}],"classes":[{"title":"VAT","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"45"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.06"},{"groupId":"OG001","value":"-0.36","spread":"0.04"},{"groupId":"OG002","value":"-0.61","spread":"0.06"},{"groupId":"OG003","value":"-0.30","spread":"0.05"},{"groupId":"OG004","value":"-0.43","spread":"0.05"},{"groupId":"OG005","value":"-0.64","spread":"0.06"},{"groupId":"OG006","value":"-0.83","spread":"0.07"},{"groupId":"OG007","value":"-0.75","spread":"0.07"},{"groupId":"OG008","value":"-0.82","spread":"0.06"}]}]},{"title":"SAT","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.07"},{"groupId":"OG001","value":"-0.51","spread":"0.10"},{"groupId":"OG002","value":"-0.87","spread":"0.10"},{"groupId":"OG003","value":"-0.54","spread":"0.07"},{"groupId":"OG004","value":"-0.80","spread":"0.10"},{"groupId":"OG005","value":"-1.00","spread":"0.07"},{"groupId":"OG006","value":"-1.15","spread":"0.09"},{"groupId":"OG007","value":"-1.10","spread":"0.10"},{"groupId":"OG008","value":"-1.37","spread":"0.10"}]}]},{"title":"Trunk fat mass","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"47"},{"groupId":"OG005","value":"42"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.24","spread":"0.49"},{"groupId":"OG001","value":"-4.51","spread":"0.53"},{"groupId":"OG002","value":"-7.65","spread":"0.63"},{"groupId":"OG003","value":"-4.45","spread":"0.61"},{"groupId":"OG004","value":"-6.31","spread":"0.56"},{"groupId":"OG005","value":"-8.41","spread":"0.48"},{"groupId":"OG006","value":"-9.97","spread":"0.49"},{"groupId":"OG007","value":"-9.52","spread":"0.63"},{"groupId":"OG008","value":"-11.52","spread":"0.47"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in VAT, SAT and Trunk Fat Mass by DXA at Week 72","description":"Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome. Number analysed are the participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Kilogram (kg)","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"32"},{"groupId":"OG006","value":"38"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"34"}]}],"classes":[{"title":"VAT","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"31"},{"groupId":"OG006","value":"37"},{"groupId":"OG007","value":"40"},{"groupId":"OG008","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"0.07"},{"groupId":"OG001","value":"-0.39","spread":"0.06"},{"groupId":"OG002","value":"-0.65","spread":"0.06"},{"groupId":"OG003","value":"-0.33","spread":"0.05"},{"groupId":"OG004","value":"-0.52","spread":"0.05"},{"groupId":"OG005","value":"-0.67","spread":"0.06"},{"groupId":"OG006","value":"-0.93","spread":"0.09"},{"groupId":"OG007","value":"-0.74","spread":"0.07"},{"groupId":"OG008","value":"-0.86","spread":"0.07"}]}]},{"title":"SAT","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"31"},{"groupId":"OG006","value":"37"},{"groupId":"OG007","value":"40"},{"groupId":"OG008","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.09"},{"groupId":"OG001","value":"-0.60","spread":"0.12"},{"groupId":"OG002","value":"-0.98","spread":"0.11"},{"groupId":"OG003","value":"-0.52","spread":"0.09"},{"groupId":"OG004","value":"-0.91","spread":"0.12"},{"groupId":"OG005","value":"-1.09","spread":"0.10"},{"groupId":"OG006","value":"-1.25","spread":"0.11"},{"groupId":"OG007","value":"-1.21","spread":"0.13"},{"groupId":"OG008","value":"-1.51","spread":"0.12"}]}]},{"title":"Trunk Fat Mass","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"32"},{"groupId":"OG006","value":"38"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.55","spread":"0.52"},{"groupId":"OG001","value":"-5.24","spread":"0.67"},{"groupId":"OG002","value":"-8.61","spread":"0.68"},{"groupId":"OG003","value":"-4.65","spread":"0.67"},{"groupId":"OG004","value":"-7.30","spread":"0.67"},{"groupId":"OG005","value":"-9.32","spread":"0.63"},{"groupId":"OG006","value":"-11.06","spread":"0.68"},{"groupId":"OG007","value":"-10.20","spread":"0.78"},{"groupId":"OG008","value":"-12.86","spread":"0.66"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Reduction in Waist Circumference Greater Than or Equal to (≥) 5 cm at Week 48","description":"Waist circumference was measured in a standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Only participants with non-missing baseline value were included in analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug and had evaluable data for this outcome.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"39"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7"},{"groupId":"OG001","value":"71.0"},{"groupId":"OG002","value":"78.4"},{"groupId":"OG003","value":"66.7"},{"groupId":"OG004","value":"82.4"},{"groupId":"OG005","value":"95.1"},{"groupId":"OG006","value":"100.0"},{"groupId":"OG007","value":"90.7"},{"groupId":"OG008","value":"97.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48","description":"Body weight was measured in kgs to the nearest 0.1 kg. Only participants with non-missing baseline value were included in analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug and had evaluable data for this outcome.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"classes":[{"title":"Reduction in ≥ 5%","categories":[{"measurements":[{"groupId":"OG000","value":"40.0"},{"groupId":"OG001","value":"58.1"},{"groupId":"OG002","value":"83.8"},{"groupId":"OG003","value":"73.3"},{"groupId":"OG004","value":"92.2"},{"groupId":"OG005","value":"97.6"},{"groupId":"OG006","value":"100.0"},{"groupId":"OG007","value":"97.7"},{"groupId":"OG008","value":"97.7"}]}]},{"title":"Reduction in ≥ 10% Body Weight","categories":[{"measurements":[{"groupId":"OG000","value":"8.6"},{"groupId":"OG001","value":"29.0"},{"groupId":"OG002","value":"51.4"},{"groupId":"OG003","value":"48.9"},{"groupId":"OG004","value":"80.4"},{"groupId":"OG005","value":"68.3"},{"groupId":"OG006","value":"92.5"},{"groupId":"OG007","value":"81.4"},{"groupId":"OG008","value":"95.3"}]}]},{"title":"Reduction in ≥ 15% Body Weight","categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"16.1"},{"groupId":"OG002","value":"32.4"},{"groupId":"OG003","value":"35.6"},{"groupId":"OG004","value":"47.1"},{"groupId":"OG005","value":"41.5"},{"groupId":"OG006","value":"55.0"},{"groupId":"OG007","value":"60.5"},{"groupId":"OG008","value":"79.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Reduction in Fat Mass ≥ 5% ≥ 10% ≥ 15% by DXA at Week 48","description":"Only participants with non-missing baseline value were included in analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug and had evaluable data for this outcome.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"47"},{"groupId":"OG005","value":"42"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"43"}]}],"classes":[{"title":"≥ 5% reduction in Fat Mass","categories":[{"measurements":[{"groupId":"OG000","value":"43.3"},{"groupId":"OG001","value":"93.3"},{"groupId":"OG002","value":"97.2"},{"groupId":"OG003","value":"80.0"},{"groupId":"OG004","value":"97.9"},{"groupId":"OG005","value":"100.0"},{"groupId":"OG006","value":"100.0"},{"groupId":"OG007","value":"100.0"},{"groupId":"OG008","value":"100.0"}]}]},{"title":"≥ 10% reduction in Fat Mass","categories":[{"measurements":[{"groupId":"OG000","value":"23.3"},{"groupId":"OG001","value":"90.0"},{"groupId":"OG002","value":"88.9"},{"groupId":"OG003","value":"64.4"},{"groupId":"OG004","value":"91.5"},{"groupId":"OG005","value":"97.6"},{"groupId":"OG006","value":"97.5"},{"groupId":"OG007","value":"97.6"},{"groupId":"OG008","value":"100.0"}]}]},{"title":"≥ 15% reduction in Fat Mass","categories":[{"measurements":[{"groupId":"OG000","value":"10.0"},{"groupId":"OG001","value":"53.3"},{"groupId":"OG002","value":"75.0"},{"groupId":"OG003","value":"53.3"},{"groupId":"OG004","value":"85.1"},{"groupId":"OG005","value":"92.9"},{"groupId":"OG006","value":"97.5"},{"groupId":"OG007","value":"90.5"},{"groupId":"OG008","value":"100.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Fat Mass ≥ 10% Reduction With <5% Decrease in Lean Mass by DXA at Week 48","description":"Only participants with non-missing baseline value were included in analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug and had evaluable data for this outcome.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"47"},{"groupId":"OG005","value":"42"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"83.3"},{"groupId":"OG002","value":"77.8"},{"groupId":"OG003","value":"26.7"},{"groupId":"OG004","value":"19.1"},{"groupId":"OG005","value":"61.9"},{"groupId":"OG006","value":"65.0"},{"groupId":"OG007","value":"76.2"},{"groupId":"OG008","value":"67.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving >5 kg Weight Loss and Fat Loss Index (FLI) of >70%, >80%, and >90% by DXA at Week 48","description":"Fat Lost Index = % change in fat mass/% change in lean mass + % change in fat mass. Only participants with non-missing baseline value were included in analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug and had evaluable data for this outcome.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"56"},{"groupId":"OG005","value":"56"},{"groupId":"OG006","value":"55"},{"groupId":"OG007","value":"56"},{"groupId":"OG008","value":"55"}]}],"classes":[{"title":">5kg Weight Loss and Fat Loss Index >70 %","categories":[{"measurements":[{"groupId":"OG000","value":"14.55"},{"groupId":"OG001","value":"26.79"},{"groupId":"OG002","value":"40.35"},{"groupId":"OG003","value":"41.82"},{"groupId":"OG004","value":"50.00"},{"groupId":"OG005","value":"62.50"},{"groupId":"OG006","value":"65.45"},{"groupId":"OG007","value":"64.29"},{"groupId":"OG008","value":"72.73"}]}]},{"title":">5kg Weight Loss and Fat Loss Index >80 %","categories":[{"measurements":[{"groupId":"OG000","value":"12.73"},{"groupId":"OG001","value":"23.21"},{"groupId":"OG002","value":"36.84"},{"groupId":"OG003","value":"16.36"},{"groupId":"OG004","value":"17.86"},{"groupId":"OG005","value":"57.14"},{"groupId":"OG006","value":"56.36"},{"groupId":"OG007","value":"53.57"},{"groupId":"OG008","value":"61.82"}]}]},{"title":">5kg Weight Loss and Fat Loss Index >90 %","categories":[{"measurements":[{"groupId":"OG000","value":"3.64"},{"groupId":"OG001","value":"19.64"},{"groupId":"OG002","value":"35.09"},{"groupId":"OG003","value":"12.73"},{"groupId":"OG004","value":"5.36"},{"groupId":"OG005","value":"42.86"},{"groupId":"OG006","value":"41.82"},{"groupId":"OG007","value":"46.43"},{"groupId":"OG008","value":"41.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Fat Mass by Bioelectrical Impedance Analysis (BIA) at Week 48","description":"Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.72","spread":"0.77"},{"groupId":"OG001","value":"-6.45","spread":"0.78"},{"groupId":"OG002","value":"-9.84","spread":"0.81"},{"groupId":"OG003","value":"-7.54","spread":"0.93"},{"groupId":"OG004","value":"-10.83","spread":"0.75"},{"groupId":"OG005","value":"-12.85","spread":"0.69"},{"groupId":"OG006","value":"-14.71","spread":"0.87"},{"groupId":"OG007","value":"-14.16","spread":"0.82"},{"groupId":"OG008","value":"-16.87","spread":"0.72"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Fat Mass by BIA at Week 72","description":"Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"44"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"39"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.69","spread":"0.87"},{"groupId":"OG001","value":"-7.20","spread":"0.97"},{"groupId":"OG002","value":"-10.24","spread":"1.00"},{"groupId":"OG003","value":"-6.49","spread":"1.12"},{"groupId":"OG004","value":"-11.56","spread":"0.95"},{"groupId":"OG005","value":"-13.94","spread":"0.97"},{"groupId":"OG006","value":"-14.86","spread":"0.92"},{"groupId":"OG007","value":"-14.95","spread":"0.97"},{"groupId":"OG008","value":"-19.43","spread":"0.97"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Body Fat by BIA at Week 48","description":"Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.49","spread":"0.38"},{"groupId":"OG001","value":"-3.82","spread":"0.45"},{"groupId":"OG002","value":"-5.70","spread":"0.46"},{"groupId":"OG003","value":"-3.80","spread":"0.65"},{"groupId":"OG004","value":"-5.18","spread":"0.43"},{"groupId":"OG005","value":"-7.03","spread":"0.42"},{"groupId":"OG006","value":"-8.47","spread":"0.68"},{"groupId":"OG007","value":"-8.39","spread":"0.61"},{"groupId":"OG008","value":"-9.33","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Body Fat by BIA at Week 72","description":"Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"44"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"39"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.63","spread":"0.45"},{"groupId":"OG001","value":"-4.36","spread":"0.54"},{"groupId":"OG002","value":"-5.65","spread":"0.57"},{"groupId":"OG003","value":"-3.06","spread":"0.75"},{"groupId":"OG004","value":"-5.46","spread":"0.56"},{"groupId":"OG005","value":"-7.43","spread":"0.62"},{"groupId":"OG006","value":"-8.29","spread":"0.66"},{"groupId":"OG007","value":"-8.71","spread":"0.63"},{"groupId":"OG008","value":"-11.33","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lean Mass by DXA at Week 48","description":"Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"47"},{"groupId":"OG005","value":"42"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"0.53"},{"groupId":"OG001","value":"1.48","spread":"0.51"},{"groupId":"OG002","value":"1.19","spread":"0.55"},{"groupId":"OG003","value":"-2.86","spread":"0.45"},{"groupId":"OG004","value":"-4.43","spread":"0.35"},{"groupId":"OG005","value":"-1.28","spread":"0.42"},{"groupId":"OG006","value":"-1.12","spread":"0.54"},{"groupId":"OG007","value":"-0.65","spread":"0.66"},{"groupId":"OG008","value":"-1.43","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lean Mass by DXA at Week 72","description":"Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\nWeeks 1 to 4: 0.25 mg Weeks 5 to 8: 0.5 mg Weeks 9 to 71: 1.0 mg."},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"32"},{"groupId":"OG006","value":"38"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","spread":"0.72"},{"groupId":"OG001","value":"2.26","spread":"0.56"},{"groupId":"OG002","value":"1.28","spread":"0.58"},{"groupId":"OG003","value":"-2.78","spread":"0.48"},{"groupId":"OG004","value":"-4.05","spread":"0.45"},{"groupId":"OG005","value":"-1.04","spread":"0.54"},{"groupId":"OG006","value":"-1.78","spread":"0.52"},{"groupId":"OG007","value":"-0.79","spread":"0.70"},{"groupId":"OG008","value":"-1.84","spread":"0.57"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lean Body Mass by DXA at Week 48","description":"Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"47"},{"groupId":"OG005","value":"42"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"0.79"},{"groupId":"OG001","value":"2.81","spread":"0.84"},{"groupId":"OG002","value":"2.39","spread":"0.93"},{"groupId":"OG003","value":"-5.23","spread":"0.79"},{"groupId":"OG004","value":"-7.90","spread":"0.60"},{"groupId":"OG005","value":"-2.21","spread":"0.78"},{"groupId":"OG006","value":"-1.92","spread":"0.85"},{"groupId":"OG007","value":"-1.00","spread":"1.01"},{"groupId":"OG008","value":"-2.51","spread":"0.87"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lean Body Mass by DXA at Week 72","description":"Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"32"},{"groupId":"OG006","value":"38"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.51","spread":"1.14"},{"groupId":"OG001","value":"4.17","spread":"0.96"},{"groupId":"OG002","value":"2.71","spread":"0.96"},{"groupId":"OG003","value":"-5.09","spread":"0.86"},{"groupId":"OG004","value":"-7.23","spread":"0.79"},{"groupId":"OG005","value":"-1.96","spread":"0.96"},{"groupId":"OG006","value":"-2.89","spread":"0.81"},{"groupId":"OG007","value":"-1.38","spread":"1.11"},{"groupId":"OG008","value":"-3.00","spread":"1.00"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 48","description":"Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"47"},{"groupId":"OG005","value":"42"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.87","spread":"0.82"},{"groupId":"OG001","value":"3.07","spread":"1.14"},{"groupId":"OG002","value":"2.47","spread":"0.96"},{"groupId":"OG003","value":"-5.68","spread":"0.89"},{"groupId":"OG004","value":"-9.43","spread":"0.77"},{"groupId":"OG005","value":"-2.31","spread":"0.79"},{"groupId":"OG006","value":"-2.22","spread":"0.91"},{"groupId":"OG007","value":"-1.74","spread":"1.00"},{"groupId":"OG008","value":"-2.28","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 72","description":"Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"32"},{"groupId":"OG006","value":"38"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.76","spread":"1.47"},{"groupId":"OG001","value":"4.98","spread":"1.16"},{"groupId":"OG002","value":"2.78","spread":"1.15"},{"groupId":"OG003","value":"-6.24","spread":"1.09"},{"groupId":"OG004","value":"-9.08","spread":"0.87"},{"groupId":"OG005","value":"-2.30","spread":"1.13"},{"groupId":"OG006","value":"-3.87","spread":"0.86"},{"groupId":"OG007","value":"-2.29","spread":"1.13"},{"groupId":"OG008","value":"-2.40","spread":"1.29"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lean Mass (kg) by BIA at Week 48","description":"Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"0.38"},{"groupId":"OG001","value":"-0.13","spread":"0.55"},{"groupId":"OG002","value":"-1.68","spread":"0.46"},{"groupId":"OG003","value":"-3.40","spread":"0.69"},{"groupId":"OG004","value":"-4.40","spread":"0.44"},{"groupId":"OG005","value":"-2.73","spread":"0.37"},{"groupId":"OG006","value":"-3.15","spread":"0.52"},{"groupId":"OG007","value":"-2.73","spread":"0.55"},{"groupId":"OG008","value":"-4.62","spread":"0.48"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lean Mass (kg) by BIA at Week 72","description":"Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"44"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"39"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.49"},{"groupId":"OG001","value":"-0.54","spread":"0.56"},{"groupId":"OG002","value":"-2.45","spread":"0.62"},{"groupId":"OG003","value":"-4.34","spread":"0.64"},{"groupId":"OG004","value":"-5.01","spread":"0.45"},{"groupId":"OG005","value":"-3.32","spread":"0.48"},{"groupId":"OG006","value":"-5.79","spread":"1.11"},{"groupId":"OG007","value":"-3.95","spread":"0.57"},{"groupId":"OG008","value":"-4.50","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lean Body Mass by BIA at Week 48","description":"Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.71","spread":"0.52"},{"groupId":"OG001","value":"3.62","spread":"0.47"},{"groupId":"OG002","value":"5.35","spread":"0.47"},{"groupId":"OG003","value":"4.02","spread":"0.67"},{"groupId":"OG004","value":"5.09","spread":"0.40"},{"groupId":"OG005","value":"6.83","spread":"0.45"},{"groupId":"OG006","value":"8.29","spread":"0.69"},{"groupId":"OG007","value":"7.23","spread":"0.92"},{"groupId":"OG008","value":"8.91","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lean Body Mass by BIA at Week 72","description":"Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"44"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"39"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.29","spread":"1.55"},{"groupId":"OG001","value":"4.05","spread":"0.57"},{"groupId":"OG002","value":"4.65","spread":"0.68"},{"groupId":"OG003","value":"2.80","spread":"1.17"},{"groupId":"OG004","value":"4.66","spread":"0.89"},{"groupId":"OG005","value":"6.52","spread":"1.41"},{"groupId":"OG006","value":"6.89","spread":"1.37"},{"groupId":"OG007","value":"6.79","spread":"1.34"},{"groupId":"OG008","value":"10.64","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Body Mass Index (BMI) Categories at Baseline and Week 48","description":"BMI categories:\n\ni. Healthy weight: 18.5 kilograms (kg)/meter (m)² to 24.9 kg/m² ii. Overweight: 25 kg/m² to 29.9 kg/m² iii. Obesity class 1: 30 kg/m² to 34.9 kg/m² iv. Obesity class II: 35 kg/m² to 39.9 kg/m² v. Obesity class III: ≥ 40 kg/m2","populationDescription":"All randomized participants who received at least one dose of the study drug and had evaluable data for this outcome at the specified timepoint.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"56"},{"groupId":"OG005","value":"56"},{"groupId":"OG006","value":"55"},{"groupId":"OG007","value":"56"},{"groupId":"OG008","value":"55"}]}],"classes":[{"title":"Healthy weight (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"56"},{"groupId":"OG005","value":"56"},{"groupId":"OG006","value":"55"},{"groupId":"OG007","value":"56"},{"groupId":"OG008","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}]}]},{"title":"Overweight (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"56"},{"groupId":"OG005","value":"56"},{"groupId":"OG006","value":"55"},{"groupId":"OG007","value":"56"},{"groupId":"OG008","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"5.4"},{"groupId":"OG002","value":"1.8"},{"groupId":"OG003","value":"14.5"},{"groupId":"OG004","value":"5.4"},{"groupId":"OG005","value":"3.6"},{"groupId":"OG006","value":"9.1"},{"groupId":"OG007","value":"1.8"},{"groupId":"OG008","value":"5.5"}]}]},{"title":"Obesity class I (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"56"},{"groupId":"OG005","value":"56"},{"groupId":"OG006","value":"55"},{"groupId":"OG007","value":"56"},{"groupId":"OG008","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.1"},{"groupId":"OG001","value":"39.3"},{"groupId":"OG002","value":"29.8"},{"groupId":"OG003","value":"27.3"},{"groupId":"OG004","value":"35.7"},{"groupId":"OG005","value":"28.6"},{"groupId":"OG006","value":"27.3"},{"groupId":"OG007","value":"25.0"},{"groupId":"OG008","value":"34.5"}]}]},{"title":"Obesity class II (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"56"},{"groupId":"OG005","value":"56"},{"groupId":"OG006","value":"55"},{"groupId":"OG007","value":"56"},{"groupId":"OG008","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"30.4"},{"groupId":"OG002","value":"38.6"},{"groupId":"OG003","value":"27.3"},{"groupId":"OG004","value":"32.1"},{"groupId":"OG005","value":"30.4"},{"groupId":"OG006","value":"29.1"},{"groupId":"OG007","value":"50"},{"groupId":"OG008","value":"27.3"}]}]},{"title":"Obesity class III (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"56"},{"groupId":"OG005","value":"56"},{"groupId":"OG006","value":"55"},{"groupId":"OG007","value":"56"},{"groupId":"OG008","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.1"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"29.8"},{"groupId":"OG003","value":"30.9"},{"groupId":"OG004","value":"26.8"},{"groupId":"OG005","value":"37.5"},{"groupId":"OG006","value":"34.5"},{"groupId":"OG007","value":"23.2"},{"groupId":"OG008","value":"32.7"}]}]},{"title":"Healthy weight (Week 48)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2.7"},{"groupId":"OG003","value":"17.8"},{"groupId":"OG004","value":"3.9"},{"groupId":"OG005","value":"2.4"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"11.6"}]}]},{"title":"Overweight (Week 48)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.4"},{"groupId":"OG001","value":"19.4"},{"groupId":"OG002","value":"21.6"},{"groupId":"OG003","value":"28.9"},{"groupId":"OG004","value":"33.3"},{"groupId":"OG005","value":"31.7"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"25.6"},{"groupId":"OG008","value":"37.2"}]}]},{"title":"Obesity class I (Week 48)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.1"},{"groupId":"OG001","value":"32.3"},{"groupId":"OG002","value":"43.2"},{"groupId":"OG003","value":"17.8"},{"groupId":"OG004","value":"51.0"},{"groupId":"OG005","value":"31.7"},{"groupId":"OG006","value":"37.5"},{"groupId":"OG007","value":"53.5"},{"groupId":"OG008","value":"27.9"}]}]},{"title":"Obesity class II (Week 48)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.4"},{"groupId":"OG001","value":"35.5"},{"groupId":"OG002","value":"21.6"},{"groupId":"OG003","value":"17.8"},{"groupId":"OG004","value":"7.8"},{"groupId":"OG005","value":"26.8"},{"groupId":"OG006","value":"22.5"},{"groupId":"OG007","value":"11.6"},{"groupId":"OG008","value":"14"}]}]},{"title":"Obesity class III (Week 48)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"40"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12.9"},{"groupId":"OG002","value":"10.8"},{"groupId":"OG003","value":"17.8"},{"groupId":"OG004","value":"3.9"},{"groupId":"OG005","value":"7.3"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"2.3"},{"groupId":"OG008","value":"9.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Baseline Waist-to-Height Ratio (WtHR) Category of <0.5 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48","description":"WHtR ratio categories: \\<0.5; 0.5-0.59; ≥0.6","populationDescription":"All randomized participants who received at least one dose of the study drug and had a baseline WtHR category \\<0.5 and had evaluable data at week 48.\n\nAs no enrolled participants had a baseline waist-to-height ratio (WtHR) below 0.5, this outcome measure was not analyzed, and no participants were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Baseline up to 48 weeks","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}]}],"classes":[{"title":"WtHR Category: <0.5"},{"title":"WtHR Category: 0.5-0.59"},{"title":"WtHR Category: ≥0.6"}]},{"type":"SECONDARY","title":"Percentage of Participants With Baseline WtHR Category of 0.5-0.59 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48","description":"WHtR ratio categories: \\<0.5; 0.5-0.59; ≥0.6","populationDescription":"All randomized participants who received at least one dose of the study drug and had Baseline WtHR Category 0.5-0.59 and had evaluable data at week 48.\n\nNo participants were included in the analysis for the \"30 mg/kg Bimagrumab\",\"10 mg/kg Bimagrumab + 2.4 mg semaglutide ,\" and \"30 mg/kg Bimagrumab + 1.0 mg semaglutide \" reporting arms, as none of the enrolled individuals in these groups had a baseline WtHR of 0.5-0.59.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline up to 48 weeks","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"4"}]}],"classes":[{"title":"WtHR Category: <0.5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"50.0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG008","value":"25.0"}]}]},{"title":"WtHR Category: 0.5-0.59","categories":[{"measurements":[{"groupId":"OG000","value":"60.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG003","value":"50.0"},{"groupId":"OG004","value":"66.7"},{"groupId":"OG005","value":"100.0"},{"groupId":"OG008","value":"75.0"}]}]},{"title":"WtHR Category: ≥0.6","categories":[{"measurements":[{"groupId":"OG000","value":"40.0"},{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"33.3"},{"groupId":"OG005","value":"0"},{"groupId":"OG008","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Baseline WtHR Category ≥0.6 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48","description":"WHtR ratio categories: \\<0.5; 0.5-0.59; ≥0.6","populationDescription":"All randomized participants who received at least one dose of the study drug and had Baseline WtHR Category ≥0.6 and had evaluable data at week 48","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline up to 48 weeks","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\nWeeks 1 to 4: 0.25 mg Weeks 5 to 8: 0.5 mg Weeks 9 to 12: 1.0 mg Weeks 13 to 16: 1.7 mg Weeks 17 to 71: 2.4 mg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"48"},{"groupId":"OG005","value":"39"},{"groupId":"OG006","value":"39"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"39"}]}],"classes":[{"title":"WtHR Category: <0.5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5.4"},{"groupId":"OG003","value":"2.6"},{"groupId":"OG004","value":"2.1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"7.7"},{"groupId":"OG007","value":"2.3"},{"groupId":"OG008","value":"15.4"}]}]},{"title":"WtHR Category: 0.5-0.59","categories":[{"measurements":[{"groupId":"OG000","value":"20.0"},{"groupId":"OG001","value":"17.9"},{"groupId":"OG002","value":"21.6"},{"groupId":"OG003","value":"25.6"},{"groupId":"OG004","value":"31.3"},{"groupId":"OG005","value":"38.5"},{"groupId":"OG006","value":"38.5"},{"groupId":"OG007","value":"51.2"},{"groupId":"OG008","value":"35.9"}]}]},{"title":"WtHR Category: ≥0.6","categories":[{"measurements":[{"groupId":"OG000","value":"80.0"},{"groupId":"OG001","value":"82.1"},{"groupId":"OG002","value":"73.0"},{"groupId":"OG003","value":"71.8"},{"groupId":"OG004","value":"66.7"},{"groupId":"OG005","value":"61.5"},{"groupId":"OG006","value":"53.8"},{"groupId":"OG007","value":"46.5"},{"groupId":"OG008","value":"48.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 48","description":"HbA1c is the glycosylated fraction of hemoglobin A. It is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of HbA1c","timeFrame":"Baseline, 48 weeks","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"49"},{"groupId":"OG005","value":"40"},{"groupId":"OG006","value":"41"},{"groupId":"OG007","value":"39"},{"groupId":"OG008","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.05"},{"groupId":"OG001","value":"-0.20","spread":"0.04"},{"groupId":"OG002","value":"-0.17","spread":"0.06"},{"groupId":"OG003","value":"-0.34","spread":"0.03"},{"groupId":"OG004","value":"-0.39","spread":"0.03"},{"groupId":"OG005","value":"-0.37","spread":"0.03"},{"groupId":"OG006","value":"-0.56","spread":"0.04"},{"groupId":"OG007","value":"-0.44","spread":"0.03"},{"groupId":"OG008","value":"-0.48","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 24","description":"The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health \"now\" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"t-score","timeFrame":"Baseline, Week 24","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"34"},{"groupId":"OG007","value":"39"},{"groupId":"OG008","value":"36"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.91","spread":"2.33"},{"groupId":"OG001","value":"9.74","spread":"1.48"},{"groupId":"OG002","value":"11.61","spread":"1.62"},{"groupId":"OG003","value":"11.50","spread":"1.56"},{"groupId":"OG004","value":"11.02","spread":"1.97"},{"groupId":"OG005","value":"12.20","spread":"1.89"},{"groupId":"OG006","value":"12.75","spread":"1.92"},{"groupId":"OG007","value":"12.71","spread":"1.94"},{"groupId":"OG008","value":"12.45","spread":"1.93"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score Week 24","description":"The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into (mental component score \\[MCS\\] and physical component score \\[PCS\\] to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Week 24","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"34"},{"groupId":"OG007","value":"39"},{"groupId":"OG008","value":"36"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.47","spread":"2.11"},{"groupId":"OG001","value":"4.69","spread":"1.98"},{"groupId":"OG002","value":"9.70","spread":"1.65"},{"groupId":"OG003","value":"11.95","spread":"1.56"},{"groupId":"OG004","value":"12.26","spread":"1.49"},{"groupId":"OG005","value":"12.96","spread":"2.02"},{"groupId":"OG006","value":"10.09","spread":"2.11"},{"groupId":"OG007","value":"13.82","spread":"1.62"},{"groupId":"OG008","value":"13.31","spread":"1.45"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 48","description":"The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health \"now\" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"t-score","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"45"},{"groupId":"OG005","value":"39"},{"groupId":"OG006","value":"34"},{"groupId":"OG007","value":"34"},{"groupId":"OG008","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.30","spread":"1.80"},{"groupId":"OG001","value":"11.72","spread":"2.51"},{"groupId":"OG002","value":"13.41","spread":"1.64"},{"groupId":"OG003","value":"11.68","spread":"2.42"},{"groupId":"OG004","value":"11.58","spread":"2.14"},{"groupId":"OG005","value":"16.34","spread":"1.55"},{"groupId":"OG006","value":"15.14","spread":"1.82"},{"groupId":"OG007","value":"15.27","spread":"1.97"},{"groupId":"OG008","value":"18.25","spread":"2.19"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 48","description":"The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"45"},{"groupId":"OG005","value":"39"},{"groupId":"OG006","value":"34"},{"groupId":"OG007","value":"34"},{"groupId":"OG008","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.02","spread":"2.08"},{"groupId":"OG001","value":"8.32","spread":"2.00"},{"groupId":"OG002","value":"11.31","spread":"1.77"},{"groupId":"OG003","value":"13.62","spread":"1.79"},{"groupId":"OG004","value":"14.27","spread":"1.67"},{"groupId":"OG005","value":"15.99","spread":"1.90"},{"groupId":"OG006","value":"16.42","spread":"1.92"},{"groupId":"OG007","value":"17.03","spread":"1.60"},{"groupId":"OG008","value":"17.69","spread":"1.90"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 72","description":"The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health \"now\" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"t-score","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"35"},{"groupId":"OG004","value":"41"},{"groupId":"OG005","value":"31"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"35"},{"groupId":"OG008","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.35","spread":"3.81"},{"groupId":"OG001","value":"13.70","spread":"2.65"},{"groupId":"OG002","value":"15.90","spread":"1.62"},{"groupId":"OG003","value":"14.06","spread":"1.75"},{"groupId":"OG004","value":"13.52","spread":"2.28"},{"groupId":"OG005","value":"17.36","spread":"1.77"},{"groupId":"OG006","value":"14.41","spread":"1.97"},{"groupId":"OG007","value":"17.04","spread":"2.20"},{"groupId":"OG008","value":"20.91","spread":"1.76"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 72","description":"The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"35"},{"groupId":"OG004","value":"41"},{"groupId":"OG005","value":"31"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"35"},{"groupId":"OG008","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.03","spread":"3.49"},{"groupId":"OG001","value":"6.96","spread":"3.02"},{"groupId":"OG002","value":"12.28","spread":"1.91"},{"groupId":"OG003","value":"13.84","spread":"2.10"},{"groupId":"OG004","value":"13.96","spread":"2.04"},{"groupId":"OG005","value":"16.98","spread":"1.91"},{"groupId":"OG006","value":"14.37","spread":"2.12"},{"groupId":"OG007","value":"18.26","spread":"1.76"},{"groupId":"OG008","value":"17.85","spread":"1.59"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score and Total Score at Week 24","description":"The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Week 24","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"47"},{"groupId":"OG005","value":"44"},{"groupId":"OG006","value":"38"},{"groupId":"OG007","value":"42"},{"groupId":"OG008","value":"36"}]}],"classes":[{"title":"Physical Function Score","categories":[{"measurements":[{"groupId":"OG000","value":"7.973","spread":"15.919"},{"groupId":"OG001","value":"13.289","spread":"13.115"},{"groupId":"OG002","value":"13.974","spread":"13.726"},{"groupId":"OG003","value":"16.667","spread":"14.616"},{"groupId":"OG004","value":"17.447","spread":"16.677"},{"groupId":"OG005","value":"14.659","spread":"16.474"},{"groupId":"OG006","value":"12.105","spread":"22.680"},{"groupId":"OG007","value":"18.690","spread":"19.818"},{"groupId":"OG008","value":"21.667","spread":"17.113"}]}]},{"title":"Total score","categories":[{"measurements":[{"groupId":"OG000","value":"8.142","spread":"11.538"},{"groupId":"OG001","value":"10.789","spread":"10.363"},{"groupId":"OG002","value":"15.513","spread":"11.868"},{"groupId":"OG003","value":"17.639","spread":"11.285"},{"groupId":"OG004","value":"19.468","spread":"13.055"},{"groupId":"OG005","value":"18.977","spread":"14.901"},{"groupId":"OG006","value":"14.671","spread":"16.434"},{"groupId":"OG007","value":"17.113","spread":"14.463"},{"groupId":"OG008","value":"22.917","spread":"14.826"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 48","description":"The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"45"},{"groupId":"OG005","value":"40"},{"groupId":"OG006","value":"37"},{"groupId":"OG007","value":"36"},{"groupId":"OG008","value":"39"}]}],"classes":[{"title":"Physical Function Score","categories":[{"measurements":[{"groupId":"OG000","value":"13.45","spread":"2.37"},{"groupId":"OG001","value":"17.96","spread":"2.37"},{"groupId":"OG002","value":"19.39","spread":"2.09"},{"groupId":"OG003","value":"16.98","spread":"2.07"},{"groupId":"OG004","value":"21.39","spread":"2.14"},{"groupId":"OG005","value":"20.62","spread":"2.62"},{"groupId":"OG006","value":"23.21","spread":"2.97"},{"groupId":"OG007","value":"26.69","spread":"2.30"},{"groupId":"OG008","value":"22.96","spread":"2.00"}]}]},{"title":"Total Score","categories":[{"measurements":[{"groupId":"OG000","value":"13.44","spread":"1.99"},{"groupId":"OG001","value":"15.62","spread":"1.92"},{"groupId":"OG002","value":"18.52","spread":"2.15"},{"groupId":"OG003","value":"19.16","spread":"1.98"},{"groupId":"OG004","value":"23.43","spread":"1.99"},{"groupId":"OG005","value":"24.33","spread":"2.11"},{"groupId":"OG006","value":"22.91","spread":"2.50"},{"groupId":"OG007","value":"24.42","spread":"2.18"},{"groupId":"OG008","value":"26.47","spread":"2.29"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 72","description":"The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'","populationDescription":"All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Week 72","groups":[{"id":"OG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64."},{"id":"OG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64."},{"id":"OG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64."},{"id":"OG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"},{"id":"OG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg"},{"id":"OG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"41"},{"groupId":"OG005","value":"32"},{"groupId":"OG006","value":"34"},{"groupId":"OG007","value":"37"},{"groupId":"OG008","value":"34"}]}],"classes":[{"title":"Physical Function Score","categories":[{"measurements":[{"groupId":"OG000","value":"12.08","spread":"3.13"},{"groupId":"OG001","value":"19.05","spread":"2.58"},{"groupId":"OG002","value":"19.34","spread":"2.45"},{"groupId":"OG003","value":"22.05","spread":"1.80"},{"groupId":"OG004","value":"25.07","spread":"2.50"},{"groupId":"OG005","value":"19.85","spread":"2.10"},{"groupId":"OG006","value":"19.30","spread":"2.37"},{"groupId":"OG007","value":"28.31","spread":"2.79"},{"groupId":"OG008","value":"29.85","spread":"2.39"}]}]},{"title":"Total Score","categories":[{"measurements":[{"groupId":"OG000","value":"14.08","spread":"2.62"},{"groupId":"OG001","value":"17.98","spread":"2.69"},{"groupId":"OG002","value":"19.12","spread":"2.23"},{"groupId":"OG003","value":"24.43","spread":"1.91"},{"groupId":"OG004","value":"25.46","spread":"2.07"},{"groupId":"OG005","value":"26.97","spread":"2.41"},{"groupId":"OG006","value":"21.47","spread":"2.49"},{"groupId":"OG007","value":"28.14","spread":"2.78"},{"groupId":"OG008","value":"32.19","spread":"2.21"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Baseline up to Week 104","description":"All randomized participants who received at least one dose of study drug. Based on the planned safety analysis, adverse events were collected per the treatment regimen, irrespective of each dose level.","eventGroups":[{"id":"EG000","title":"Placebo/30 mg/kg Bimagrumab","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64.","deathsNumAffected":0,"deathsNumAtRisk":55,"seriousNumAffected":5,"seriousNumAtRisk":55,"otherNumAffected":46,"otherNumAtRisk":55},{"id":"EG001","title":"10/30 mg/kg Bimagrumab","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64.","deathsNumAffected":0,"deathsNumAtRisk":56,"seriousNumAffected":9,"seriousNumAtRisk":56,"otherNumAffected":54,"otherNumAtRisk":56},{"id":"EG002","title":"30 mg/kg Bimagrumab","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64.","deathsNumAffected":0,"deathsNumAtRisk":57,"seriousNumAffected":8,"seriousNumAtRisk":57,"otherNumAffected":54,"otherNumAtRisk":57},{"id":"EG003","title":"Placebo + 1.0 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg","deathsNumAffected":0,"deathsNumAtRisk":55,"seriousNumAffected":4,"seriousNumAtRisk":55,"otherNumAffected":52,"otherNumAtRisk":55},{"id":"EG004","title":"Placebo + 2.4 mg Semaglutide","description":"Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg","deathsNumAffected":0,"deathsNumAtRisk":56,"seriousNumAffected":8,"seriousNumAtRisk":56,"otherNumAffected":52,"otherNumAtRisk":56},{"id":"EG005","title":"10 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg","deathsNumAffected":0,"deathsNumAtRisk":56,"seriousNumAffected":7,"seriousNumAtRisk":56,"otherNumAffected":53,"otherNumAtRisk":56},{"id":"EG006","title":"10 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg","deathsNumAffected":0,"deathsNumAtRisk":55,"seriousNumAffected":8,"seriousNumAtRisk":55,"otherNumAffected":54,"otherNumAtRisk":55},{"id":"EG007","title":"30 mg/kg Bimagrumab + 1.0 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 71: 1.0 mg","deathsNumAffected":0,"deathsNumAtRisk":56,"seriousNumAffected":6,"seriousNumAtRisk":56,"otherNumAffected":54,"otherNumAtRisk":56},{"id":"EG008","title":"30 mg/kg Bimagrumab + 2.4 mg Semaglutide","description":"Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule:\n\n* Weeks 1 to 4: 0.25 mg\n* Weeks 5 to 8: 0.5 mg\n* Weeks 9 to 12: 1.0 mg\n* Weeks 13 to 16: 1.7 mg\n* Weeks 17 to 71: 2.4 mg","deathsNumAffected":0,"deathsNumAtRisk":55,"seriousNumAffected":7,"seriousNumAtRisk":55,"otherNumAffected":54,"otherNumAtRisk":55}],"seriousEvents":[{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Diarrhoea haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Intussusception","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Mallory-weiss syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Mesenteric artery aneurysm","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Obstructive pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Gallbladder disorder","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gallbladder enlargement","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gallbladder polyp","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Appendicitis perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Arthritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Giardiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Haematoma infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Otitis externa","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Perineal cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pilonidal disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Post-acute covid-19 syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rectal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Viral rash","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Post procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Compartment syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vertebral foraminal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Bowen's disease","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ovarian adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Squamous cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Squamous cell carcinoma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Tonsillar hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Increased tendency to bruise","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Splenomegaly","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Aortic valve disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Atrioventricular block first degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Left ventricular hypertrophy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cerumen impaction","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Ear congestion","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hyperacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Motion sickness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tympanic membrane perforation","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Goitre","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Oestrogen deficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Thyroid mass","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Blepharospasm","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Extraocular muscle disorder","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Eye swelling","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Eyelid disorder","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Eyelid ptosis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ocular hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Periorbital dermatitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Periorbital oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Periorbital swelling","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Photopsia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Posterior capsule opacification","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Retinal tear","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Swelling of eyelid","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vitreous floaters","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG004","numEvents":10,"numAffected":10,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":57},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG005","numEvents":7,"numAffected":7,"numAtRisk":56},{"groupId":"EG006","numEvents":7,"numAffected":7,"numAtRisk":55},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG008","numEvents":10,"numAffected":10,"numAtRisk":55}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":9,"numAffected":9,"numAtRisk":55},{"groupId":"EG007","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Abdominal tenderness","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Aphthous ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Bowel movement irregularity","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Change of bowel habit","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":11,"numAffected":11,"numAtRisk":55},{"groupId":"EG004","numEvents":16,"numAffected":16,"numAtRisk":56},{"groupId":"EG005","numEvents":8,"numAffected":8,"numAtRisk":56},{"groupId":"EG006","numEvents":15,"numAffected":15,"numAtRisk":55},{"groupId":"EG007","numEvents":17,"numAffected":17,"numAtRisk":56},{"groupId":"EG008","numEvents":9,"numAffected":9,"numAtRisk":55}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dental discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dental pulp disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":55},{"groupId":"EG001","numEvents":27,"numAffected":27,"numAtRisk":56},{"groupId":"EG002","numEvents":29,"numAffected":29,"numAtRisk":57},{"groupId":"EG003","numEvents":19,"numAffected":19,"numAtRisk":55},{"groupId":"EG004","numEvents":21,"numAffected":21,"numAtRisk":56},{"groupId":"EG005","numEvents":27,"numAffected":27,"numAtRisk":56},{"groupId":"EG006","numEvents":29,"numAffected":29,"numAtRisk":55},{"groupId":"EG007","numEvents":25,"numAffected":25,"numAtRisk":56},{"groupId":"EG008","numEvents":27,"numAffected":27,"numAtRisk":55}]},{"term":"Diarrhoea haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Diverticulum","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Diverticulum intestinal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":55},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Faeces soft","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Frequent bowel movements","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastrointestinal motility disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastrointestinal sounds abnormal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG006","numEvents":9,"numAffected":9,"numAtRisk":55},{"groupId":"EG007","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG008","numEvents":9,"numAffected":9,"numAtRisk":55}]},{"term":"Glossodynia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Hyperaesthesia teeth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypoaesthesia oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Impaired gastric emptying","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Infrequent bowel movements","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Intestinal metaplasia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Irritable bowel syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":55},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":56},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":57},{"groupId":"EG003","numEvents":25,"numAffected":25,"numAtRisk":55},{"groupId":"EG004","numEvents":26,"numAffected":26,"numAtRisk":56},{"groupId":"EG005","numEvents":23,"numAffected":23,"numAtRisk":56},{"groupId":"EG006","numEvents":34,"numAffected":34,"numAtRisk":55},{"groupId":"EG007","numEvents":20,"numAffected":20,"numAtRisk":56},{"groupId":"EG008","numEvents":27,"numAffected":27,"numAtRisk":55}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Oral discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Palatal polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Paraesthesia oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Proctalgia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Proctitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Retching","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Spigelian hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Tongue spasm","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tooth disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tooth impacted","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":55},{"groupId":"EG004","numEvents":10,"numAffected":10,"numAtRisk":56},{"groupId":"EG005","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG006","numEvents":10,"numAffected":10,"numAtRisk":55},{"groupId":"EG007","numEvents":7,"numAffected":7,"numAtRisk":56},{"groupId":"EG008","numEvents":8,"numAffected":8,"numAtRisk":55}]},{"term":"Administration site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Catheter site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Complication associated with device","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cyst","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Drug withdrawal syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Early satiety","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Exercise tolerance decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":57},{"groupId":"EG003","numEvents":13,"numAffected":13,"numAtRisk":55},{"groupId":"EG004","numEvents":15,"numAffected":15,"numAtRisk":56},{"groupId":"EG005","numEvents":7,"numAffected":7,"numAtRisk":56},{"groupId":"EG006","numEvents":11,"numAffected":11,"numAtRisk":55},{"groupId":"EG007","numEvents":8,"numAffected":8,"numAtRisk":56},{"groupId":"EG008","numEvents":12,"numAffected":12,"numAtRisk":55}]},{"term":"Feeling abnormal","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Feeling cold","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Feeling hot","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hernia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hunger","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Impaired healing","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":57},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":55},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":56},{"groupId":"EG005","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG007","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Infusion site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Infusion site extravasation","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Infusion site rash","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Infusion site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Infusion site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Injection site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":55}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Swelling face","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Temperature intolerance","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Therapeutic response unexpected","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vaccination site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Vessel puncture site bruise","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cholecystitis chronic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hepatic atrophy","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hepatic cyst","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hepatic steatosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hepatomegaly","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypertransaminasaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Food allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Immunisation reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Abdominal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Acne pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Acute sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Asymptomatic bacteriuria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Bacterial vaginosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Beta haemolytic streptococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Body tinea","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Breast cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Chlamydial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":55},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":56},{"groupId":"EG002","numEvents":16,"numAffected":16,"numAtRisk":57},{"groupId":"EG003","numEvents":15,"numAffected":15,"numAtRisk":55},{"groupId":"EG004","numEvents":18,"numAffected":18,"numAtRisk":56},{"groupId":"EG005","numEvents":12,"numAffected":12,"numAtRisk":56},{"groupId":"EG006","numEvents":12,"numAffected":12,"numAtRisk":55},{"groupId":"EG007","numEvents":10,"numAffected":10,"numAtRisk":56},{"groupId":"EG008","numEvents":12,"numAffected":12,"numAtRisk":55}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Ear infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ear infection fungal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Escherichia urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"External ear cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Eye infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Fungal foot infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastrointestinal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Genital candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Gingival abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gonorrhoea","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hand-foot-and-mouth disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Helicobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Herpes virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Hordeolum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Infected bite","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Infected cyst","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Infective exacerbation of bronchiectasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Kidney infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Labyrinthitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Mastitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Metapneumovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG005","numEvents":7,"numAffected":7,"numAtRisk":56},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG007","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Omphalitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Onychomycosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Otitis externa","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Penile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pharyngitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pneumonia viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Post procedural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Post viral fatigue syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Post-acute covid-19 syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pustule","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Respiratory syncytial virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":55}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Rhinovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin bacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin candida","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tinea infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tinea pedis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tonsillitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Tracheobronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":55},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":56},{"groupId":"EG002","numEvents":13,"numAffected":13,"numAtRisk":57},{"groupId":"EG003","numEvents":14,"numAffected":14,"numAtRisk":55},{"groupId":"EG004","numEvents":17,"numAffected":17,"numAtRisk":56},{"groupId":"EG005","numEvents":11,"numAffected":11,"numAtRisk":56},{"groupId":"EG006","numEvents":10,"numAffected":10,"numAtRisk":55},{"groupId":"EG007","numEvents":16,"numAffected":16,"numAtRisk":56},{"groupId":"EG008","numEvents":17,"numAffected":17,"numAtRisk":55}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG007","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG008","numEvents":7,"numAffected":7,"numAtRisk":55}]},{"term":"Vaginal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vestibular neuronitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Vulval abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vulvovaginal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vulvovaginal mycotic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Arthropod sting","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Back injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Bone contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Burn oral cavity","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cartilage injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Chest injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Epicondylitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Eye contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Foreign body in skin or subcutaneous tissue","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gingival injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Incision site pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Ligament rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Limb crushing injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Meniscus injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Muscle injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Muscle rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Neck injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Periorbital haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Post procedural contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Post procedural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Procedural dizziness","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Procedural headache","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Procedural nausea","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Scar","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Seroma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Stress fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sunburn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Synovial rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tendon injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tooth fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Traumatic haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ulna fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Wound complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Activated partial thromboplastin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG007","numEvents":7,"numAffected":7,"numAtRisk":56},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":55},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":56},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":57},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG005","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG006","numEvents":10,"numAffected":10,"numAtRisk":55},{"groupId":"EG007","numEvents":9,"numAffected":9,"numAtRisk":56},{"groupId":"EG008","numEvents":8,"numAffected":8,"numAtRisk":55}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood folate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood iron decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood magnesium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood phosphorus decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood pressure decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Blood pressure diastolic increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Bone density decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Cardiac murmur","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Electrocardiogram qt prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Electrocardiogram t wave inversion","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Eosinophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Glomerular filtration rate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Heart rate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Heart rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Heart rate irregular","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hepatic enzyme abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Human metapneumovirus test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG007","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":55}]},{"term":"Lipids increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Liver function test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Liver function test increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Nitrite urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pancreatic enzymes increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Prothrombin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Red blood cell sedimentation rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Red blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Urine albumin/creatinine ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Urine analysis abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Urine bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Vitamin b12 decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vitamin d decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"White blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Abnormal weight gain","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Appetite disorder","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":57},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":55},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":56},{"groupId":"EG005","numEvents":10,"numAffected":10,"numAtRisk":56},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":55},{"groupId":"EG007","numEvents":8,"numAffected":8,"numAtRisk":56},{"groupId":"EG008","numEvents":7,"numAffected":7,"numAtRisk":55}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dyslipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Food intolerance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Glucose tolerance impaired","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Increased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Iron deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Polydipsia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vitamin d deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":57},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":55},{"groupId":"EG004","numEvents":9,"numAffected":9,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG007","numEvents":8,"numAffected":8,"numAtRisk":56},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":55}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Axillary mass","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":57},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG004","numEvents":8,"numAffected":8,"numAtRisk":56},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG006","numEvents":9,"numAffected":9,"numAtRisk":55},{"groupId":"EG007","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Bone cyst","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Bursitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Cervical spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Coccydynia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Compartment syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Costochondritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dupuytren's contracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Exostosis of jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Fibromyalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Inguinal mass","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Joint effusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Joint instability","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Joint range of motion decreased","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Joint stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Limb discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Medial tibial stress syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Muscle contracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Muscle fatigue","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":55},{"groupId":"EG001","numEvents":27,"numAffected":27,"numAtRisk":56},{"groupId":"EG002","numEvents":41,"numAffected":41,"numAtRisk":57},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":55},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG005","numEvents":32,"numAffected":32,"numAtRisk":56},{"groupId":"EG006","numEvents":36,"numAffected":36,"numAtRisk":55},{"groupId":"EG007","numEvents":36,"numAffected":36,"numAtRisk":56},{"groupId":"EG008","numEvents":35,"numAffected":35,"numAtRisk":55}]},{"term":"Muscle tightness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Muscle twitching","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Musculoskeletal discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":9,"numAffected":9,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Osteochondritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Osteonecrosis of jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Pain in jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Patellofemoral pain syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Periarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Plantar fasciitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Sacral pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sarcopenia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Synovial cyst","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Temporomandibular joint syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tendon discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tendon disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tendonitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Trigger finger","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Trismus","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Acrochordon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Benign neoplasm of thyroid gland","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Colorectal adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Haemangioma of liver","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Haemangioma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Intraductal papilloma of breast","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Lipoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Melanocytic naevus","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Seborrhoeic keratosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ageusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Allodynia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Burning sensation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Carpal tunnel syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cerebral atrophy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cervical radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cubital tunnel syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Disturbance in attention","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG004","numEvents":8,"numAffected":8,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":55}]},{"term":"Dizziness postural","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Dysaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG008","numEvents":7,"numAffected":7,"numAtRisk":55}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":55},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":56},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":57},{"groupId":"EG003","numEvents":10,"numAffected":10,"numAtRisk":55},{"groupId":"EG004","numEvents":13,"numAffected":13,"numAtRisk":56},{"groupId":"EG005","numEvents":10,"numAffected":10,"numAtRisk":56},{"groupId":"EG006","numEvents":12,"numAffected":12,"numAtRisk":55},{"groupId":"EG007","numEvents":13,"numAffected":13,"numAtRisk":56},{"groupId":"EG008","numEvents":9,"numAffected":9,"numAtRisk":55}]},{"term":"Hyperaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Hyporeflexia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Lumbar radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Migraine with aura","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Nerve compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Radicular pain","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Restless legs syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Taste disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Tension headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Thoracic radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Tongue biting","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Device breakage","organSystem":"Product Issues","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Abnormal dreams","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Affective disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Attention deficit hyperactivity disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Bipolar disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dysphoria","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Grief reaction","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Mixed anxiety and depressive disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Mood altered","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Negative thoughts","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Nightmare","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Parasomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Poor quality sleep","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Premature ejaculation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Restlessness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Stress","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Albuminuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Bladder pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":55}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Micturition urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Nocturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sterile pyuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ureteric obstruction","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Urinary hesitation","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Urine odour abnormal","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Abnormal uterine bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Amenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Breast cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Breast mass","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Cervical polyp","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Endometriosis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gynaecomastia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Haematospermia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Heavy menstrual bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Intermenstrual bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Menopausal symptoms","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Menstrual disorder","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Menstruation delayed","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Menstruation irregular","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Ovarian cyst ruptured","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ovarian disorder","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pelvic pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Polycystic ovaries","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Postmenopausal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Prostatomegaly","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Testicular pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Uterine polyp","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vaginal discharge","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vaginal prolapse","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vulvovaginal pruritus","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Nasal septum deviation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Obstructive sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Oropharyngeal discomfort","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Paranasal sinus inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pulmonary hilum mass","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pulmonary mass","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Respiratory disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rhinalgia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sinonasal obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Snoring","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Throat irritation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Throat tightness","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Tonsillar hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Upper-airway cough syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":55},{"groupId":"EG001","numEvents":22,"numAffected":22,"numAtRisk":56},{"groupId":"EG002","numEvents":28,"numAffected":28,"numAtRisk":57},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":55},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":56},{"groupId":"EG005","numEvents":24,"numAffected":24,"numAtRisk":56},{"groupId":"EG006","numEvents":25,"numAffected":25,"numAtRisk":55},{"groupId":"EG007","numEvents":31,"numAffected":31,"numAtRisk":56},{"groupId":"EG008","numEvents":29,"numAffected":29,"numAtRisk":55}]},{"term":"Acne cystic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Actinic keratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Androgenetic alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Blister","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Chloasma","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dermal cyst","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":55}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Granuloma annulare","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Hand dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hirsutism","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypertrichosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypohidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypotrichosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ingrowing nail","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Intertrigo","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Keloid scar","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Nail growth abnormal","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Onychoclasis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pain of skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Papule","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Petechiae","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Photosensitivity reaction","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pigmentation disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Psoriasis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":55},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":56},{"groupId":"EG005","numEvents":8,"numAffected":8,"numAtRisk":56},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":55},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":56},{"groupId":"EG008","numEvents":6,"numAffected":6,"numAtRisk":55}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Rosacea","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Scab","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Seborrhoea","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Seborrhoeic dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sensitive skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Skin burning sensation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin discolouration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Skin disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin irritation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin mass","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Skin odour abnormal","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Menopause","organSystem":"Social circumstances","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Postmenopause","organSystem":"Social circumstances","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Dental implantation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Lipoma excision","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Angiopathy","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Bleeding varicose vein","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":56},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":57},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":55},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Iliac artery occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Superficial vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Varicose vein","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":57},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Varicose vein ruptured","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":57},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":55},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":56},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":55}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2024-04-09","uploadDate":"2025-06-23T13:51","filename":"Prot_002.pdf","size":4893863},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-07-10","uploadDate":"2025-06-23T13:51","filename":"SAP_003.pdf","size":1452225}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09","removedCountries":["Brazil"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-06-05","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D009765","term":"Obesity"},{"id":"D050177","term":"Overweight"}],"ancestors":[{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000596367","term":"bimagrumab"},{"id":"C000591245","term":"semaglutide"}]}},"hasResults":true}